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Background: RNA binding proteins (RBPs) play a fundamental role in posttranscriptional control of gene
expression. Different RBPs have oncogenic or tumor-suppressive functions on human cancers. RNPC1 belongs to
the RNA recognition motif (RRM) family of RBPs, which could regulate expression of diverse targets by mRNA
stability in human cancer cells. Several studies reported that RNPC1 played an important role in cancer, mostly
acting as an oncogene or up-regulating in tumors. However, its role in human breast cancer remains unclear.
Methods: In the present study, we investigated the functional and mechanistic roles of RNPC1 in attenuating
invasive signal including reverse epithelial-mesenchymal transition (EMT) to inhibit breast cancer cells
aggressiveness in vitro. Moreover, RNPC1 suppress tumorigenicity in vivo. Further, we studied the expression
of RNPC1 in breast cancer tissue and adjacent normal breast tissue by quantitative RT-PCR (qRT-PCR) and
Western blot.
Results: We observed that RNPC1 expression was silenced in breast cancer cell lines compared to breast epithelial
cells. More important, RNPC1 was frequently silenced in breast cancer tissue compared to adjacent normal breast
tissue. Low RNPC1 mRNA expression was associated with higher clinical stages and mutp53, while low level of
RNPC1 protein was associated with higher lymph node metastasis, mutp53 and lower progesterone receptor (PR).
Functional assays showed ectopic expression of RNPC1 could inhibit breast tumor cell proliferation in vivo and
in vitro through inducing cell cycle arrest, and further suppress tumor cell migration and invasion partly through
repressing mutant p53 (mutp53) induced EMT.
Conclusions: Overall, our findings indicated that RNPC1 had a potential function to play a tumor-suppressor role
which may be a potential marker in the therapeutic and prognostic of breast cancer.
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Breast cancer is the most commonly diagnosed cancer
in women and the leading cause of cancer deaths in the
developed world [1]. Despite advances to diagnose and
treat breast cancer keeping growing, the incidence is still
rising, and it remains a major fatal disease in women [2].
Breast cancer is a heterogeneous disease due to com-
plicated etiology, results from accumulated genetic and
epigenetic alterations of various cancer genes, including
tumor-suppressor genes (TSGs) and oncogenes [3]. RNA
binding proteins (RBPs) have been realized as novel layer* Correspondence: dingqiang@njmu.edu.cn
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sion as TSGs or oncogenes.
RBPs play a key role in posttranscriptional control of
gene expression [4], such as polyadenylation, RNA spli-
cing, transport, stability, and translation, all of which are
emerging as critical mechanisms for gene regulation in
mammalian cells [5]. RBPs contain one or more RNA-
binding motifs, such as hnRNP K homology motif, RNA
recognition motif (RRM), RGG box, and dsRBD motif
[5-7]. RRM is the most prevalent type of eukaryotic
RNA-binding motifs [6]. RBPs are involved in the ex-
pression of various genes responsible for biological pro-
cesses and cellular functions, so expected mutations or
aberrant production of RBPs can cause cancer progres-
sion [7,8]. Deregulation of splicing factors might lead to. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the other hand, translation of mRNA is also a regulatory
point for the expression of tumor suppressors or onco-
genes in cancer cells [10]. Therefore translation factors
play critical role in tumorigenesis. Translation initiation
factor could be over-expressed in various tumor and be-
have as a characteristic proto-oncogene [4].
RNPC1 gene is located on chromosome 20q13 and
expressed in various tissues. It belongs to the RRM family
of RBPs, is expressed as RNPC1a with 239 amino acids
and RNPC1b with 121 amino acids [11]. RNPC1a is
capable of regulating biological characteristics, binding
and stabilizing the mRNA of p21, p73 and Hu antigen R
(HUR) [11-13]. Recently, RNPC1 is also found to bind and
stabilize the mRNA of Macrophage inhibitory cytokine-1
(MIC), which facilitates RNPC1-induced cell growth sup-
pression [14]. Additional mRNAs bound by RNPC1 in-
clude p63, murine double minute-2 (MDM2) and p53
mRNAs. In these instances, RNPC1 binding mediates a
decrease in mRNA levels and attenuation of translation
[15-17]. It is solidly confirmed that RNPC1 play pivotal
roles in regulating wide biological processes, ranging from
cell proliferation, cell cycle arrest to cell myogenic differ-
entiation [13,18]. However, its role in tumorigenesis is
scanty and contradictory in human cancers, particularly in
breast cancer. In many studies, RNPC1 was recognized as
an oncogene, frequently amplified in prostate cancer
[19,20], ovarian cancer [21], colorectal cancer [22,23],
chronic lymphocytic leukemia [24], colon carcinoma [25],
esophageal cancer [26], dog lymphomas [17], and breast
cancer [27,28]. Recently, new evidence suggested RNPC1
might act as a tumor suppressor. It was reported to be in
a negative feedback loop, which restricts E2F1 activity by
limiting cell-cycle progression at the G1-S boundary [29].
Expression of RNPC1 is highly correlated with increased
survival in human ovarian cancer [29]. Moreover, RNPC1
was silenced by promoter hypermethylation in breast can-
cer [30]. However, most of the available studies focused on
the various targets of RNPC1 binding in cancer. Its ex-
pression and biologic functions in human breast cancer
remains unclear.
In this study, we showed that RNPC1 was significantly
down-regulated in high-invasive breast cancer cell lines,
MDA-MB-231 and SUM1315, not low-invasive MCF-7
cell lines. RNPC1 potentiated tumor-suppressive signals to
suppress proliferation, growth, migration, and invasiveness
of breast cancer cells in vitro, and suppress tumorigenicity
in vivo. Importantly, we examined RNPC1 expressive situ-
ation in clinical cancer and adjacent normal breast speci-
mens and analyzed the association with between RNPC1
expression and clinic pathological characters. RNPC1 was
found to be lower expressed in breast cancer compared to
adjacent normal breast tissue. RNPC1 mRNA expression
was associated with clinical stages and mutp53. RNPC1protein expression was associated with lymph node metas-
tasis, mutp53 and progesterone receptor (PR). The clinical
data was consistent with the experimental results; both of
them strongly suggested that RNPC1 might act as a tumor
suppressor in breast cancer.
Methods
RNA extraction, reverse transcription and quantitative
RT-PCR (qRT-PCR)
Total RNA was extracted from cells and tissues using Tri-
zol reagent (TaKaRa, A-79061), and cDNA was synthe-
sized using Primescript RT Reagent (TaKaRa) following






qRT-PCR for β-actin and other genes was performed
for every cDNA sample. All PCR reactions were per-
formed using the fluorescent SYBR Green I methodology.
Real-time quantitative PCR was performed on StepOne
Plus Real-Time PCR system (Applied Biosystems, USA)
using FastStart Universal SYBR Green Master (Roche,
Switzerland) according to the manufacturer's instruc-
tions. As a result, the relative gene expression was nor-
malized, with β-actin serving as the internal control.
Noticeable, this study showed clearly RNPC1instead of
RNPC1a.
Tissue samples
121 pairs of snap-frozen breast tumor and matched nor-
mal tissues from adjacent regions were provided by the
First Affiliated Hospital with Nanjing Medical Univer-
sity from February 2006 to August 2009, from patients
treated surgically for clinical stage I–III breast cancer
(aged 34–82 years). All the patients did not receive
chemotherapy, radiotherapy or hormone therapy before
surgery. Tumor and normal tissue samples had been
verified as tumor or non-tumor by histopathological
examination of hematoxylin stained paraffin sections.
Histologic types were classified according to the World
Health Organization (2003). TNM staging was defined
according to the American Joint Committee on Cancer
(AJCC) (the 6th version, 2002). All the cases were indi-
vidually categorized by independent pathologists. All
the samples’ collection was according to the ethical
guidelines of the Declaration of Helsinki and approved
by the ethics and research committee of the First Affili-
ated Hospital of Nanjing Medical University. Before sur-
gery patients are informed that their surgical specimens
would possibly be used for research purposes. All the
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for inclusion in the data analysis and manuscript publi-
cation. Data were analyzed anonymously.
Cell culture
The human breast cancer cell lines (MCF-7, MDA-MB-
231, BT474 and ZR-75) and non-malignant breast epithe-
lial cells (MCF-10A) were obtained from the American
Type Culture Collection (ATCC, VA, USA) and culture in
complete medium of High glucose Dulbecco's Modified
Eagle Medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), 1% penicillin - streptomycin solution
at 5% CO2 and 37°C incubator. Cell line SUM1315 was
provided by Stephen Ethier (University of Michigan). The
184A1 immortalized breast epithelial cell line was pro-
vided by Ceshi Chen (Kunming Institute of Zoology).
Plasmid construction and lentivirus packaging
Lentivirus packaging cells were transfected with PGLV3-
h1-GFP-puro vector (GenePharma, Shanghai, China)
or pGLV5-h1-GFP-puro vector (GenePharma, Shanghai,
China) containing either the RNPC1a knockdown
(shRNPC1a) or RNPC1a overexpression (RNPC1a), and a
scrambled sequence (SCR) or a negative control sequence
(NC), respectively, following the manufacturer’s instruc-
tions. Three shRNA plasmids (sh1, sh2, sh3) were con-
structed against different RNPC1a targets, including a
scrambled sequence as a negative control (Additional
file 1: Table S1). All plasmids were verified by sequencing
(GenePharma, Shanghai, China). Cells were plated in 6
wells dishes at 30% confluence and infected with the retro-
viruses. Meanwhile, polybrene (5 μg/ml) was added with
the retroviruses to enhance the target cells infection effi-
ciency. Stable pooled populations of breast cancer cells
were generated by selection using puromycin (2 μg/ml)
for 2 weeks. For knockdown, one construct (sh3), with
≥85% knockdown efficiency, was used for further studies
(Additional file 1: Figure S1).
Colony formation assay
Cell used for colony formation analysis were seeded into
6-well plates (500 cells/wells) and cultured normally for
15–20 days. The colonies were fixed in paraform and
stained with Giemsa after washed by phosphate-buffered
saline (PBS) twice, then dried at room temperature. The
colonies in each well were counted, and all cell colonies
contained 50 or more cells.
Cell counting kit (CCK-8) assay
Cell proliferation was assessed using CCK-8 kit (Dojindo,
Japan) according to the manufacturer’s instructions/proto-
col. Cells diluted serum-free medium, 2,000 cells/wells
were seeded in a 96-well cell culture plate, grown at 37°C
on the day of measuring the growth rate of cells, 100 μl ofspent medium was replaced with an equal volume of fresh
medium containing 10% CCK8, then cells continued to be
incubated at 37°C for 3 h, and the absorbance was finally
determined at 450 nm using a micro plate reader (5082
Grodig, Tecan, Austria).Wound healing assay
Breast cancer cells were seeded into 6-well plates, and
allowed to grow until 100% confluens. Then the cell layer
was gently scratched through the central axis using a ster-
ile plastic tip and loose cells were washed away. Quantifi-
cation of cell motility by measuring the distance between
the invading fronts of cells in three random selected
microscopic fields (200×) for each condition and time
point (0, 18 h).Cell migration and invasion assays
In vitro cell migration and invasion assays were per-
formed as described previously [31]. Images of three
random fields (200×) were captured from each mem-
brane, and the number of migratory or invasive cells was
counted.Tumorigenesis in nude mice
BALB/C female nude mice (4-6-weeks old, 18–22 g)
were randomly divided into two groups (each containing
7 mices). Stable RNPC1a-expression MDA-MB-231 cells
or control cells (1 × 106 cells in 0.1 ml PBS) was subcuta-
neously orthotopically injected into mammary fat pads
of the mice and the growth of tumors was followed up
for 6 weeks. Tumor volume was measured weekly using
a caliper, calculated as (tumor length × width2)/2. After
6 weeks, mice were sacrificed and checked for final
tumor size. Mouse studies were conducted according to
the Guide for the Care and Use of Laboratory Animals
and approved by the Animal Care and Use Committee
of Nanjing Medical University. All the samples’ collec-
tion was according to the ethical guidelines of the Dec-
laration of Helsinki and approved by the ethics and
research committee of the First Affiliated Hospital of
Nanjing Medical University.Western blotting analysis
Western blot analysis was performed as described previ-
ously [32]. The primary antibodies used were anti-rabbit
RBM38 (Santa Cruz), p21 (Santa Cruz), p53 (Santa Cruz),
p53 (Millipore), Vimentin (Abcam), anti-mouse E-cadherin
(Abcam). The secondary antibodies were purchased from
Cell Signaling technology. The intensity of the bands was
determined using densitometric analysis. GAPDH (Santa
Cruz) was used to as loading control.
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Cell cycle was assessed by flow cytometry (Becton
Dickinson, San Jose, CA, USA). For cell cycle analysis,
cells were collected, washed with PBS and fixed in ethanol
at −20°C for 8 h before being collected by centrifugation.
Then cells were washed with PBS, and resuspended in
500 μl of PBS with 0.2% Triton X-100, 10 mM EDTA,
100 μg/ml RNase A, and 50 μg/ml propidium iodide (PI)
at room temperature for 30 min.
Statistical analysis
The data were analyzed using the SPSS 12.0 software
(SPSS, Chicago, IL, USA). All experiments in this study
were repeated in triplicate, unless otherwise specified.
Student t-test was used to analyze the statistical signifi-
cance of the differences between groups. χ2 test andFigure 1 RNPC1 expressive in breast cancer cell lines and tissues. (A)
cancer cell lines and normal breast cell lines MCF-10A and 184A1. The two
other cell lines (p < 0.05). The fold change of RNPC1a is shown below each
analysis. (B) RNPC1 mRNA expression in 121 pairs of breast cancer and adja
of RNPC1 mRNA in 121 pairs of human breast cancer tissues and adjacent
RNPC1, where the breast cancer tissues showed the lower level of expressi
cancer and adjacent tissues. The 25 kDa band/GAPDH ratio was markedly l
for example. The fold change of RNPC1a is shown below each lane. The int
(E) A scatter plot of RNPC1 protein expression in the same cancer tissue, a
mean ± SEM, *p < 0.05, **p < 0.01.Fisher Exact test were used to assess the correlation
between RNPC1 and clinicopathologic parameters. For
all the tests p values < 0.05 was considered statistically
significant.
Results
RNPC1 was lower expressed in human breast cancer cells
RNPC1 expression in five breast cancer cell lines and
two breast epithelial cell lines were quantified by qRT-
PCR and Western blot (Figure 1A, p < 0.05). Among the
seven cell lines analyzed, RNPC1 was found lower ex-
pression in breast cancer cells compared to normal
mammary breast epithelial MCF-10A and 184A1 cells.
Among breast cancer cells, MCF-7, BT474, ZR-75 cells
expressed relatively higher levels of RNPC1, and low
expression or barely detectable levels were found inqRT-PCR and Western blot analysis of RNPC1 expression in breast
normal breast cell lines showed higher expression of RNPC1 than
lane. The intensity of the bands was determined using densitometric
cent tissue. 26 cases showed for example. (C) Average expression level
normal breast tissues. Adjacent breast tissues had higher expression of
on (p < 0.01). (D) RNPC1 protein expression in 121 pairs of breast
ower in tumors compared to adjacent normal tissues. 12 cases showed
ensity of the bands was determined using densitometric analysis.
djacent tissue (p < 0.05). Data were means of two separate experiments
Table 1 The association between RNPC1 mRNA expression











≤55 68 42 26 0.109
>55 53 40 13
Tumor Size (cm)
≤2 38 24 14 0.463
>2 83 58 25
TNM stage
I 24 11 13 0.010
II + III 97 71 26
Lymph node
metastasis
≤3 96 69 27 0.058
>3 25 13 12
Grade
I 7 2 5 0.066
II 67 50 17
III 30 18 12
unclear 17 12 5
ER status
Negative 40 22 18 0.097
Positive 70 51 19
unclear 11 9 2
PR status
Negative 58 42 16 0.294
Positive 63 40 23
Her2 status
Negative 81 56 25 0.298
Positive 32 19 13
suspect 8 7 1
Ki67
≤15% 43 30 13 0.430
>15% 52 40 12
CK5/6
Negative 46 35 11 0.830
Positive 15 11 4
P53
Negative 42 26 16 0.042
Positive 52 42 10
Table 1 The association between RNPC1 mRNA expression
and clinicopathologic features of breast cancer (Continued)
PCNA
Negative 2 1 1 0.567
+ 36 27 9
++ 22 18 4
+++ 12 8 4
Histology
ductal 106 71 35 0.622
special 15 11 4
ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal
growth factor receptor 2.
TNM classification according to the Union Internationale Contre le Cancer
criteria. HER2 positivity 3+ in immunohistochemistry or positive fluorescent in
situ hybridisation test.
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that clearly MB-231 could instead of MDA-MB-231.RNPC1 protein and mRNA expression were down-regulated
in human breast cancer tissue
To determine RNPC1 expression in breast cancer tissues,
we use qRT-PCR and Western blot to analyze mRNA and
protein of RNPC1 in 121 breast cancer tissues and
marched adjacent non-cancerous tissue. RNPC1 tran-
scripts were expressed at varying levels in the primary
breast tumors analyzed. We determined a gene expression
cut-off value of 0.61 (median value) that differentiated be-
tween RNPC1 low expression and high expression in
breast cancer. Similar to the cell lines’ data, of the 121
paired samples, 82 (68%) showed significantly lower
RNPC1 mRNA expression in the breast cancer tissue
compared to the adjacent tissue. Partial data was showed
in Figure1B and 1C (p < 0.01), mean level of RNPC1 in
tumors and tumor-adjacent normal tissue was 24.52,
37.58, respectively, which suggested that down-regulation
of RNPC1 was common in breast cancer. In Western blot
analysis, 84 (69%) patients showed significantly lower
RNPC1a expression in the breast cancer tissue compared
to the adjacent normal tissue, partial data was showed in
Figure 1D. The comparison obtained by calculating the ra-
tio between RNPC1a and GAPDH expression (Figure 1E,
p < 0.05) also showed RNPC1a expression in tumors was
lower than the adjacent tissues (mean: 0.87, 1.37). Table 1
displayed the association of RNPC1 expression level and
clinicopathological features of 121 breast cancer patients,
which demonstrated that low RNPC1 mRNA expression
was significantly associated with advanced clinical stages
(p = 0.010), mutp53 (p = 0.042). In addition, it was related
with lymph node metastasis (p = 0.058) and grade (p =
0.066). There was no significant correlation between
RNPC1 mRNA expression and patient age, tumor size,
Ki67, PCNA, CK5/6, histology, estrogen receptor (ER),
Table 2 The association between RNPC1 protein expression











≤55 68 46 22 0.631
>55 53 38 15
Tumor Size (cm)
≤2 38 25 13 0.557
>2 83 59 24
TNM stage
I 24 15 9 0.411
II + III 97 69 28
Lymph node
metastasis
≤3 96 62 34 0.024
>3 25 22 3
Grade
I 7 4 3 0.215
II 67 51 16
III 30 20 10
unclear 17 9 8
ER status
Negative 40 24 16 0.181
Positive 70 53 17
unclear 11 7 4
PR status
Negative 58 46 12 0.023
Positive 63 38 25
Her2 status
Negative 81 61 20 0.117
Positive 32 18 14
suspect 8 5 3
Ki67
≤15% 43 30 13 0.402
>15% 52 32 20
CK5/6
Negative 46 29 17 0.800
Positive 15 10 5
P53
Negative 42 32 10 0.039
Positive 52 29 23
Table 2 The association between RNPC1 protein expression
and clinicopathologic features in breast cancer (Continued)
PCNA
Negative 2 2 0 0.619
+ 36 27 9
++ 22 16 6
+++ 12 7 5
Histology
ductal 106 75 31 0.397
special 15 9 6
ER: oestrogen receptor; PR: progesterone receptor; HER2: human epidermal
growth factor receptor 2.
TNM classification according to the Union Internationale Contre le Cancer
criteria. HER2 positivity 3+ in immunohistochemistry or positive fluorescent in
situ hybridisation test.
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growth factor receptor 2 (HER2). Table 2, showed that
RNPC1 protein expression was significantly associated
with lymph node metastasis (p = 0.024), mutp53 (p =
0.039) and PR (p = 0.023). There was no significant correl-
ation between RNPC1 protein expression and patient age,
advanced clinical stages, Ki67, PCNA, CK5/6, histology, or
ER status and HER2.RNPC1a inhibited proliferation and growth in human
breast cancer cells in vitro
To further address the functions of RNPC1 in breast can-
cer cells, we infected MCF-7 cells and MDA-MB-231 cells
and selected stably infected cells. The over-expressed
cell lines were named as MCF-7-RNPC1a or MB-231-
RNPC1a, while the matched control cell lines were named
as MCF-7-NC or MB-231-NC, respectively. The silenced
cell line was named as MCF-7-shRNPC1a or MB-231-
shRNPC1a, while the matched control cell lines were
named as MCF-7-SCR or MB-231-SCR, respectively. We
confirmed the expression levels using both Western blot
(Figure 2A and E) and qRT-PCR (Figure 2B and F, both
p < 0.001).
The growth of the stable cell lines over 6 days was deter-
mined using Cell counting kit (CCK-8) assay. As shown in
Figure 2C and Figure 2D, RNPC1a overexpression led to
significantly decreased cell proliferation (p < 0.05), while
RNPC1a knockdown led to significantly increased cell
proliferation (Figure 2G and H, both p < 0.05). To further
study the mechanism by which RNPC1a overexpression
or knockdown affected proliferation, cell cycle progression
was analyzed using flow cytometry. MCF-7-RNPC1a cells
showed a delayed G1 phase compared to MCF-7-NC
cells (65.28 ± 1.495 vs 54.28 ± 1.121) (Figure 3B, p <
0.05), while MB-231-RNPC1a cells also showed a delayed
G1 phase compared to MB-231-NC cells (37.74 ± 2.559 vs
Figure 2 Effect of RNPC1a on proliferation and growth of breast cancer cell lines MCF-7 and MB-231. (A) Western blot and (B) qRT-PCR
were used to verify the efficiency of RNPC1a overexpression. The fold change of RNPC1a protein is shown below each lane. The intensity of the
bands was determined using densitometric analysis. (C, D) The growth of cells over 6 days was measured using cell counting kit (CCK-8) assays.
RNPC1a indicates RNPC1a overexpressing MCF-7 and MB-231 cells; NC indicates MCF-7 and MB-231 cells transfected with a vector-expressing
GFP. The proliferation rate of MCF-7-RNPC1a and MB-231-RNPC1a was significantly decreased compared with control cells, respectively.
Data were means of three separate experiments mean ± SEM, p < 0.05. (E) Western blot and (F) qRT-PCR were used to verify the efficiency of
RNPC1a-knockdown. The fold change of RNPC1a protein is shown below each lane. The intensity of the bands was determined using
densitometric analysis. (G, H) MCF-7-shRNPC1a and MB-231-shRNPC1a were significantly increased compared with control cells, respectively.
Data were means of three separate experiments mean ± SEM,*p < 0.05, ***p < 0.001.
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pression inhibited the proliferation of breast cancer cells
via a delay in cell cycle progression. We obtained the si-
milar results in RNPC1a knockdown MCF-7 (Additional
file 2: Figure S2).
Since anchorage-independent growth is strongly corre-
lated with tumorigenicity [33]. The ability of MCF-7 or
MB-231 cell lines to form colonies was much fewerwhen RNPC1a was over-expressed (Figure. 3C, p < 0.05).
The ability of MCF-7 or MB-231 cell lines to form col-
onies was much more when RNPC1a was knockdown
(Figure. 3D, p < 0.05).
RNPC1a suppressed migratory and invasive potential
As shown in Figure 4A and C, determined by their migra-
tion in the wound gap after 18 h, distance migrated of
Figure 3 RNPC1a suppressed anchorage dependent growth of breast cancer cells. (A, B) Cell cycle progression was measured using flow
cytometry. The progression of MCF-7-RNPC1a and MB-231-RNPC1a cells was arrest in the G1 phase compared with control cells, respectively.
Representative photographs (upper) and quantification (lower) are shown. (C) The growth of cells over 15 days was measured using colony
formation assays. Clone formation of RNPC1a overexpression arbitrarily set at 100% in control cells (NC). The number and size of MCF-7-RNPC1a
or MB-231-RNPC1a was significantly decreased compared to control cells, respectively. Representative photographs (lower) and quantification
(upper) are shown. Data were means of three separate experiments mean ± SEM, p < 0.05. (D) Clone formation of RNPC1a knockdown arbitrarily
set at 100% in knockdown (shRNPC1a) cells. The number and size of MCF-7-shRNPC1a or MB-231-shRNPC1a was significantly increased compared
with control cells, respectively. Representative photographs (lower) and quantification (upper) are shown. Data were means of three separate
experiments mean ± SEM, p < 0.05. Colonies > 50 mm were counted. Anchorage–dependent growth assays were shown at the bottom.
Data were means of three separate experiments mean ± SEM, *p < 0.05.
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p < 0.01), while RNPC1a knockdown increased by 110 μm
(Figure 4C, p < 0.01) compared to the control cells, re-
spectively. We conducted three-dimensional cell migra-
tion assay using transwell chambers and invasion assay
with Matrigel-precoated transwell chambers. We found
that RNPC1a overexpression exhibited significantly de-
crease ability of migration and invasion (Figure 4B, both
p < 0.01). RNPC1a knockdown exhibited significantly in-
crease ability of migration and invasion (Figure 4D, bothp < 0.05). Besides, we obtained the similar results of MCF-
7 cells (Additional files 3: Figure S3).
RNPC1a down-regulate mutp53 and up-regulate p21
protein expression in breast cancer cells
Previous study affirmed that translational of wild-type
p53 (wtp53) was repressed by RNPC1a [17]. However,
our study found wtp53 protein was no significantly al-
tered in RNPC1a over-expressed or silent MCF-7 cells
(Figure 5A). Level of p21 protein was increased in RNPC1a
Figure 4 RNPC1a significantly decreased migratory and invasive potential of breast cancer cells. (A, C) Wound healing assay. Images of
wound repair were taken at 0, 18 h after wound. The distance of wound closure is shown by area at 18 h. Representative photographs (upper)
and quantification (lower) are shown, original magnification, ×200. (B, D) Transwell migration assay and Matrigel invasion assay. Representative
photographs (upper) and quantification (lower) are shown. Columns: average of three independent experiments, *p < 0.05, **p < 0.01, original
magnification, ×200.
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and B). Mutp53 protein was decreased in RNPC1a
over-expressed MDA-MB-231 cells. When RNPC1a was
silenced, p21 protein was decreased in MCF-7 and MDA-
MB-231 cells, while mutp53 was increased (Figure 5B).RNPC1a up-regulate E-cadherin and down-regulate
vimentin protein expression in breast cancer cells
We observed that the RNPC1a knockdown in MCF-7 cells
led to a spindle-shaped fibroblastic morphology. This mor-
phological change might suggest the phenotypic change of
Figure 5 RNPC1a regulated p53, p21, E-cadherin and vimentin in breast cancer cell. (A) RNPC1a positively regulated p21, while there was
no significantly correlation was found between RNPC1a and wtp53 in MCF-7 cells. (B) RNPC1a positively regulated p21, while negatively regulated
mutp53 in MDA-MB-231 cells. (C) RNPC1a positively regulated E-cadherin, while negatively regulated Vimentin in MDA-MB-231 cells. (D) RNPC1a
positively regulated of E-cadherin, while there was no significantly correlation was found between RNPC1a and Vimentin in MCF-7 cells. The fold
change of RNPC1a is shown below each lane. Arbitrarily set at 1.0 in control cells. The intensity of the bands was determined using
densitometric analysis.
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cells lost their fibroblast-like morphology, which was ac-
companied by a cobblestone-like epithelial morphology
(data not shown). As shown in Figure 5C and Figure 5D
the levels of E-cadherin expression was increased in the
RNPC1a over-expressed cells, while decreased in the
RNPC1a knockdown cells. The levels of Vimentin expres-
sion was increased in the RNPC1a knockdown MDA-MB-
231 cells, while decreased in the RNPC1a over-expressed
cells in MDA-MB-231. But MCF-7 cells were not obvi-
ously changed in the protein level of the mesenchymal
markers such as Vimentin.RNPC1a suppressed tumorigenesis in nude mice
To evaluate the tumor-suppressive functions of RNPC1a
in vivo, tumorigenicity of MDA-MB-231 cells expressing
RNPC1a was evaluated in nude mice. Over-expressed
RNPC1a and control cells were injected into mammary fat
pads of the mice. Control cells were discovered tumors
after 2 weeks, while tumors derived from over-expressed
RNPC1a cells were discovered after 4 weeks (Figure 6A,
p < 0.05). RNPC1a over-expressed cells formed smaller
tumor volume and weight compared to the control cells
(Figure 6B, p < 0.01).Discussion
This study focused on the biological functions of RNPC1
and its potential clinical value in breast cancer. Among the
seven breast cell lines analyzed, RNPC1 was found to be
lower expressed in breast cancer cells compared to breast
epithelial cells. It implied a suppressive function of RNPC1
in breast cancer. Consistent with this, overexpression of
RNPC1 could reduce, whereas knockdown of RNPC1
could accelerate growth rate and number of colonies for-
mation of breast cancer cells. In cancer, proliferation is
mostly driven by altered cell cycle progression, apoptosis,
or both [34]. Other studies reported that overexpression of
RNPC1 could induce cell cycle arrest in G1 in colon can-
cer RKO [11] and osteosarcoma U2OS [29]. Cell cycle ar-
rest in G1 was also observed in RNPC1 expressed breast
cancer cells. Conversely, RNPC1 knockdown induced cell
cycle progression. Meanwhile, we observed that p21 was
changed concomitantly with RNPC1, suggesting RNPC1
in part induce cell cycle arrest in G1 via binding to and
stabilizing p21 transcript [11,35]. Further in vivo data fi-
nally supported the suppressive function of RNPC1 in
breast cancer cells. RNPC1 over-expressed MDA-MB-231
formed smaller tumor in nude mice compared to the con-
trol cell. These results were well consisted with experi-
mental data both in vitro and in vivo.
Figure 6 RNPC1a suppressed tumor growth in nude mice.
(A) RNPC1a over expressed (RNPC1a) MDA-MB-231 cells formed
smaller tumor volume compared to the control cells (NC).
(B) RNPC1a overexpression reduced tumor weight compared to
the control cells (NC). Data were means of experiments mean ± SEM,
*p < 0.05, **p < 0.01.
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of cancer [36]. In recent years, epithelial-mesenchymal
transition (EMT) has been proved to be an important step
during the progress from primary tumor to metastases
[37,38]. EMT is required for normal mammary gland
development [39] and breast cancer progression [40].
Among the tested cell lines, RNPC1 barely expressed in
mesenchymal phenotype breast cancer cell lines compared
to the epithelial breast cancer cell lines. We also observed
that MDA-MB-231 cells lost their fibroblast-like morph-
ology, when RNPC1 was over-expressed, and transformed
to a cobblestone-like epithelial morphology. Inspiring of
that, we supposed that RNPC1 might inhibit migration
and invasion of breast cancer cells by regulating EMT. By
regulating RNPC1 expression, we found E-cadherin waspromoted in the RNPC1 overexpression breast cancer cell
lines, whereas Vimentin level was reduced.
Mutations of p53 tumor suppressor was often highly
expressed and has a long half-life in various tumor [41].
Mutp53, is the commonest genetic variation detected in
primary breast cancer [42], which has various types of
functions requiring therapeutic targeting [43]. Former
study found RNPC1 and wtp53 were negative feedback
loop [17]. RNPC1 overexpression inhibited mutp53 in
colon cancer [17]. We first reported that RNPC1 over-
expression decreased mutp53 protein expression in
breast cancer. Mutp53 could induce partial EMT-like
transitions reflected in the ability to suppress E-
cadherin synthesis [44,45]. It implied that mutp53 may
participate in RNPC1 regulated process of EMT. The
mechanisms about how RNPC1 regulate transcriptional
factors to inhibit EMT are requiring more investigation
in the future.
Based on clinical samples, we observed that RNPC1 was
widely expressed in non-cancerous normal breast tissues
but frequently down-regulated in breast cancer tissue,
consisting with the in vitro data. The clinic RNPC1 low
expression may be explained by promoter hypermethyla-
tion correlates with wtp53 status [30]. By analyzing the
clinic data from 121 pairs of specimens, we found signifi-
cantly negative correlation between RNPC1 mRNA ex-
pression and mutp53, clinical stages; significantly negative
correlation between RNPC1 protein expression and lym-
phonode metastasis; significantly positive correlation be-
tween RNPC1 protein expression and PR. The same trend
was also found between RNPC1 and mutp53protein.
These results were well consisted with experimental data
both in vitro and in vivo.
Since RNPC1 is one of p53’s targets, the level of
RNPC1 in breast cancer may depend on the p53 status.
Thus, it is also possible that the correlation between
RNPC1 mRNA and clinical stages actually represents
the correlation between the p53 status and clinical
stages. Just like ER regulating PR pathway, and both of
them making the most important molecular markers of
breast cancer, RNPC1 could develop to a novel molecu-
lar maker as a downstream factor of p53.Conclusions
In summary, RNPC1 was frequently loss or low-expressed
in breast cancer. RNPC1 inhibits breast cancer cells prolif-
eration and further suppressed tumor-cell migration and
invasion. RNPC1 significantly negative correlated between
RNPC1 protein and mutp53, lymphonode metastasis, clinic
stage. It suggested RNPC1 acting as a functional tumor
suppressor in breast tumorigenesis and metastasis. RNPC1
may become a potential marker in the therapeutic or prog-
nostic practice of breast cancer.
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Additional file 1: Table S1. RNPC1a shRNA sequences. Figure S1.
Identification of stably transfected MCF-7 and MB-231 cells. (A, C)
Western blot was used to verify the efficiency of knockdown. The cells
transduced with the three shRNAs and one control shRNA are designated
as ‘sh1’, ‘sh2’, ‘sh3’ and ‘SCR’. RNPC1a-knockdown MCF-7 and MB-231 cells
had 85% lower expression when compared with SCR cells. The fold
change of RNPC1a is shown below each lane. Arbitrarily set at 1.0 in
control cells. The intensity of the bands was determined using
densitometric analysis. (B, D) qRT-PCR was used to detect RNPC1a
expression. The results are similar to those seen in the Western blot analyses.
Data were means of two separate experiments mean ± SEM, * p < 0.05.
Additional file 2: Figure S2. Cell cycle was progress in RNPC1a
knockdown MCF-7 cells. (A) The progression of MCF-7-SCR cells was more
arrested in the G1 phase compared to MCF-7-shRNPC1a cells.
(B) Histogram of cell cycle analyses. Data were means of three separate
experiments mean ± SEM, *p < 0.05.
Additional file 3: Figure S3. RNPC1a decreased migration and invasion
in MCF-7 cells. (A) The number of migrating and invading cells was
higher in MCF-7-NC than the MCF-7-RNPC1a cells. (B) The number of
migrating and invading cells was lower in MCF-7-SCR than the MCF-7-
shRNPC1a cells. Data presented average number of cells/field for three
fields. (C, D) Columns: average data of three independent experiments,
mean ± SEM, *p < 0.05, ***p < 0.001.
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